Efficacy, Safety, and Immunogenicity of Biosimilar XSB-001 vs Reference Ranibizumab in Patients With Neovascular AMD
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Randomized Trial of Biosimilar XSB-001 versus Reference Ranibizumab in Patients with Neovascular Age-Related Macular Degeneration
Ophthalmol Retina 2023 Sep 01;7(9)753-761, A Loewenstein, N Czumbel, J Ernest, J Dusová, J Pearlman, A NowosielskaFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.